Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosis

Author： Fernandez Oscar Berger Thomas Hartung Hans-Peter Putzki Norman

ISSN： 1751-2433

Source： Expert Review of Clinical Pharmacology, Vol.5, Iss.6, 2012-11, pp. : 649-665

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prolonged-release fampridine: a guide to its use in multiple sclerosis in the EU

By Lyseng-Williamson Katherine A.

Drugs & Therapy Perspectives, Vol. 28, Iss. 12, 2012-12 ,pp. : 1-4

Adis International

Access to resources Recommend Favorite

Sustained release oral fampridine in the treatment of multiple sclerosis

By Kachuck Norman J

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 12, 2009-08 ,pp. : 2025-2035

Informa Healthcare

Access to resources Recommend Favorite

Intramuscular prolonged-release paliperidone palmitate: a guide to its use in schizophrenia

Drugs & Therapy Perspectives, Vol. 27, Iss. 11, 2011-11 ,pp. : 1-5

Adis International

Access to resources Recommend Favorite

Prolonged-Release Nicotinic Acid: A Review of its Use in the Treatment of Dyslipidaemia

By McCormack Paul L. Keating Gillian M.

Drugs, Vol. 65, Iss. 18, 2005-01 ,pp. : 2719-2740

Adis International

Access to resources Recommend Favorite

Prolonged-Release Ciprofloxacin

By Foster Rachel H. Keam Susan J.

American Journal of Drug Delivery, Vol. 4, Iss. 2, 2006-01 ,pp. : 113-120

Adis International

Access to resources Recommend Favorite